34 results about "Viral immunization" patented technology

The invention discloses sgRNAs of a specific targeting grass carp RIOK3 gene and a construction method and application of an RIOK3 gene knockout cell line, and belongs to the technical field of gene engineering. The invention provides sgRNAs of a specific targeting grass carp RIOK3 gene and a sequence of a primer group, and also provides a method for constructing a large-fragment knockout cell line of the RIOK3 gene in combination with the sgRNAs, and application of the gene knockout cell line in research on an anti-virus infection mechanism of grass carp. The invention discloses the construction of the grass carp gene in-vitro research model by knocking out the antiviral negative regulatory factor RIOK3 of the fish cells by using the CRISPR-Cas9 technology for the first time, provides an in-vitro research material and a new way for the analysis of an antiviral immune regulation molecular mechanism of the grass carp, and particularly has important guiding significance for the research of resisting grass carp reovirus infection.

Disclosed herein are compositions and methods for eliciting an immune response to an antigen. More particularly, disclosed herein are compositions suitable for eliciting immune responses to a plurality of viruses, including Epstein-Ban vims (EBV), cytomegalovirus (CMV), polyoma BK vims (BKV), polyoma JC vims (JCV), and adenovims (Adv), and methods of using such compositions for treatment and prophylaxis.

The invention, in some aspects, relates to compositions comprising modified viral nucleocapsid (N) proteins and their encoding polynucleotides and methods of using such compositions and preparations to increase viral N protein dimerization and / or increase antigenicity of viral immunization preparations.

The invention belongs to the technical field of virus immunodetection, and relates to detection of swine transmissible gastroenteritis virus, in particular to a Mab 12H6 antibody, a colloidal gold test strip and application. According to the invention, TGEV N protein is used as an antigen of a detection line, Mab 12H6 is used as a detection antibody combined with colloidal gold, condition optimization is carried out through different methods, the specificity and sensitivity of the methods are evaluated, and a detection method for detecting the antigen based on an N protein TGEV colloidal gold competition method is established. The established TGEV colloidal gold test strip has the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of TGEV in a porcine diarrhea sample clinically.

The present invention is in the field of viral immunotherapy. The invention provides 1) an efficient recombinant poxvirus expressing a toxic conditional gene product that affects the viability of the recombinant poxvirus itself if left unregulated, or 2) a recombinant poxvirus expressing a conditional gene product with an improved safety profile, a method of producing them, a composition comprising them and therapeutic uses related thereto.

The invention belongs to the technical field of virus immunodetection, and relates to a Mab 6B7 antibody, a colloidal gold test strip and application. According to the invention, PDCoV N protein is used as an antigen of a detection line, Mab 6B7 is used as a detection antibody combined with colloidal gold, condition optimization is carried out through different methods, the specificity and sensitivity of the methods are evaluated, and a detection method for detecting the antigen based on an N protein PDCoV colloidal gold competition method is established. The established PDCoV colloidal gold test strip has the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of PDCoV in a porcine diarrhea sample clinically.

The application discloses a novel goose parvovirus VP1 protein truncated body gene, a recombinant duck plague virus and application. The novel goose parvovirus VP1 protein truncated body gene has a nucleotide sequence shown as SEQ ID No. 1. The recombinant duck plague virus has the novel goose parvovirus VP1 protein truncated body gene inserted into the genome of the recombinant duck plague virus. The application obtains a novel goose parvovirus VP1 protein truncated body gene, inserts the truncated body into the genome of the recombinant duck plague virus, and obtains the recombinant duck plague virus, and the rsVP1-Cre immune group shortens the NGPV discharge in the duck body, and the duck body immune rsVP1-Cre is helpful to the NGPV discharge. It is shown that the recombinant duck plague virus with the VP1 protein truncated body gene inserted can be used for preparation of a novel goose parvovirus-duck plague virus double live vector vaccine.

This invention provides novel compositions and methods for effectively stimulating antiviral immunity. [Solution] A composition comprising (a) a vector comprising a plasmid encoding at least one viral antigen; and (b) a vector comprising a CD1d recognition antigen; and (c) at least one pharmaceutically acceptable carrier, wherein at least one of vectors (a) and (b) is an intact bacterial minicell or a dead bacterial cell.

The application discloses a PEDV S protein N-glycosylation site mutant virus and application thereof. The application immunizes mice with the mutant virus to detect the influence of N-glycosylation of S protein on virus immunogenicity, and it is found that the recombinant PEDV virus strain with single-point mutation of N216, N324 and N1261 glycosylation sites of S protein can activate mice to produce a higher level of neutralizing antibody, and can be increased by 3.2 times (N216A), 6.7 times (N324A) and 3.2 times (N1261A). The recombinant PEDV virus strains with mutation of the three sites can be used as potential PEDV inactivated vaccine candidate strains.

The present disclosure relates to an immune composition comprising or encoding a human respiratory syncytial virus antigen, selected from the group consisting of a nucleic acid immune composition, a polypeptide immune composition or a viral immune composition.

The invention belongs to the technical field of virus immunity, and particularly relates to a hantavirus nucleocapsid protein pan-MHC-I epitope peptide, a vaccine and application. The pan-MHC-I epitope peptide of the hantavirus nucleocapsid protein is at least one of amino acid sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 4. The epitope peptide is used for preparing the vaccine, the immune effect of the vaccine is verified, and meanwhile, the epitope peptide is used for evaluating the effectiveness of the vaccine in the prior art. The invention clarifies the immunological characteristics of hantavirus NP antigens and the application potential of the hantavirus nucleocapsid protein pan-MHC-I epitope peptides in virus infection, disease progression and prevention. The hantavirus nucleocapsid protein pan-MHC-I epitope peptide and the corresponding vaccine are developed by using the MHC-I epitope, and CD8 + T cell response can be remarkably enhanced and activated, so that the defect of singly using the MHC-II epitope is overcome.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus (CSFV) recombinant E2 protein and application, and relates to the technical field of biology.The TK / gE double gene deletion PRV attenuated strain is used as a virus carrier, an exogenous CSFV E2 gene with a transmembrane region removed is inserted after a PRV gC signal peptide sequence, and a recombinant virus rPRV-delTK / gE-gC-E2 for expressing the gC N terminal and fusing with the PRV gC is constructed; Western blotting analysis and indirect immunofluorescence detection prove that the gC-E2 protein is successfully expressed.The recombinant virus immunized mice can produce specific antibodies against E2; after immunizing piglets, the piglets can produce an antibody level equivalent to that of a classical CSFV attenuated vaccine strain C strain.The rPRV-delTK / gE-gC-E2 obtained in the research is a promising bivalent live vaccine candidate strain.

The application provides a kind of biotinylated ferritin complex and its preparation method and application, belong to virus immune detection technical field.The biotinylated ferritin complex of the application inserts biotin receptor peptide (BAP) into Loop region, is obtained by co-transforming escherichia coli with recombinant plasmid pET28a-BAP-HFn and pETDuet-BirA (Loop-Biotin-HFn).It is assembled with HRP labeled streptavidin (SA-HRP) according to 1:26 molar ratio, and Loop-BNC complex is obtained.The Loop-BNC can be used as signal amplification probe, and is used for the detection of SARS-CoV-2 N protein by using sandwich ELISA method, and the detection sensitivity is lower than 0.0001 ng / mL, the detection effect is optimal in 0.0001-0.1 ng / mL, with the advantages of high signal-to-noise ratio and strong specificity.The application retains the high loading capacity and structural stability of ferritin, realizes the early and accurate detection of SARS-CoV-2 N protein, and provides efficient and reliable technical support and probe material for novel coronavirus detection.

The invention belongs to the technical field of virus immunodetection, and relates to a colloidal carbon test strip for detecting swine transmissible gastroenteritis virus based on a nano antibody and application of the colloidal carbon test strip. According to the TGEV colloidal carbon detection method established by the invention, Mab 12H6 is screened as a carbon labeled antibody, the concentration of N protein coated by a T line is 0.7 mg / mL, the use amount of a probe is 6 [mu] L, and the detection time is 10 min, a virus solution (5 * 10 < 4 > TCID50) with the antigen content of 1 / 256 can be sensitively detected, the specificity is good, and the detection coincidence rate of clinical test products is 95.2%. The test strip has the advantages of high specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of TGEV in a porcine diarrhea sample clinically.

The invention relates to the technical field of fish genetic breeding, in particular to a gene FTR100 related to a crucian carp interferon antiviral immune response and application of the gene FTR100. Gene related to the antiviral immune response of the crucian carp interferon is FTR100, the invention further discloses three specific knockout targets of the FTR100 gene, the crucian carp FTR100 gene is specifically knocked out by utilizing a CRISPR / Cas9 gene editing technology, and a mutant genotype individual with three alleles terminated in advance, namely the crucian carp with high resistance to the crucian carp herpesvirus, is obtained. According to the invention, the function of the FTR100 in the prussian carp is verified for the first time, a new germplasm with improved capability of resisting the herpesvirus of the prussian carp is rapidly obtained by knocking out a single gene of the FTR100, and the method has important industrial value.

The invention discloses a recombinant pseudorabies virus strain for expressing hog cholera virus recombinant E2 protein and application, and relates to the technical field of biology. According to the research, a TK / gE double-gene deleted PRV attenuated strain is used as a virus vector, and after an exogenous CSFV E2 gene without a transmembrane region is inserted into a PRV gG signal peptide sequence, a recombinant virus rPRV-delTK / gE-gG-E2 which is positioned at a gG N end and is subjected to fusion expression with PRV gG is constructed; western blotting analysis and indirect immunofluorescence detection prove that the gG-E2 protein is successfully expressed. A recombinant virus immunized mouse can generate a specific antibody aiming at E2; after piglets are immunized, an antibody level equivalent to that of a classical CSFV attenuated vaccine strain C strain can be generated. The rPRV-delTK / gE-gG-E2 obtained by the research is a bigeminy live vaccine candidate strain with an extremely promising prospect.

The invention belongs to the technical field of virus immunodetection, and relates to a colloidal carbon test strip based on a nano antibody and application of the colloidal carbon test strip in detection of porcine deltacoronavirus. According to the invention, PDCoV N protein is used as an antigen of a detection line, Mab 6B7 is used as a detection antibody combined with colloidal carbon, condition optimization is carried out through different methods, the specificity and sensitivity of the methods are evaluated, and a detection method for detecting the antigen based on the N protein PDCoV colloidal carbon competition method is established. The established PDCoV colloidal carbon detection test strip has the advantages of high specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of PDCoV in a porcine diarrhea sample clinically.

The invention belongs to the technical field of medicines, and discloses application of baicalein in preparation of related medicines for treating human coronavirus 229E infected pneumonia. Specifically, the invention discloses application of baicalein in preparation of medicines playing a protective role in prevention and / or treatment of respiratory dysfunction, lung injury, inflammatory response, virus infection and immune disorder caused by human coronavirus 229E infected pneumonia. Pharmacological experiments prove that baicalein can improve the respiratory function in human coronavirus 229E infected pneumonia, exert anti-inflammatory, anti-virus and immunoregulation effects, and can improve pulmonary edema, thereby achieving the purpose of treatment.

The invention belongs to the technical field of medicines, and discloses application of a Dayuan drink extract in related medicines for treating human coronavirus 229E infected pneumonia. Specifically, the invention discloses application of a Dayuan drink extract in preparation of drugs for protecting respiratory dysfunction, lung injury, inflammatory response, virus infection and immune disorder caused by human coronavirus 229E infected pneumonia. Pharmacological experiments prove that the Dayuan drink extract can improve the respiratory function in human coronavirus 229E infected pneumonia, exert anti-inflammatory, antiviral and immunoregulation effects, and can improve pulmonary edema, thereby achieving the purpose of treatment.

The invention discloses application of long-chain non-coding RNA (LncRNA) XR002626937.1 in regulation and control of replication of canine coronavirus (CCoV), and belongs to the technical field of biological medicine. The nucleotide sequence of the LncRNA XR002626937.1 is as shown in SEQ ID No.1, is mainly positioned in a cell nucleus, is remarkably up-regulated in time and dose dependence after MDCK cells are infected by CCoV, and is positively correlated with virus load. Functional experiments prove that overexpression of the LncRNA can significantly promote CCoV replication, and knock-down of the expression of the LncRNA can effectively inhibit virus proliferation; the action mechanism comprises the steps of inhibiting activation of a p53 signal channel and downstream target genes p21 and Bax, repressing apoptosis of infected cells, antagonizing expression of natural immune factors such as RIG-I, MAVS, ISG15 and the like, promoting virus immune escape, and being capable of serving as competitive endogenous RNA to adsorb miR-10926-z to regulate and control the downstream signal channel. The key function of the LncRNA XR002626937.1 in CCoV infection is defined for the first time, a new target spot and a theoretical basis are provided for developing the anti-CCoV medicine targeting the LncRNA, and the application prospect is wide.

The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.

Present invention provides a method of producing clarified virus pool of virus to obtain a lyophilized / freeze-dried live attenuated virus immunogenic composition / formulation comprising atleast one or more than one antigens / immunogens. Present invention provides a method of producing a clarified virus pool of viruses such as measles, mumps, rubella. It provides the improved large scale affordable / safe manufacturing processes (encompassing cultivation, purification & formulation stages) that utilize minimum animal origin components, provide high virus yield, ensure virus integrity / stability preservation across manufacturing & storage.

The invention provides a Chinese herbal medicine functional additive for shrimp breeding feed as well as a preparation method and application of the Chinese herbal medicine functional additive, and belongs to the technical field of feed additives. The Chinese herbal medicine functional additive is prepared from the following raw materials in parts by mass: 10 to 15 parts of honeysuckle flower, 10 to 15 parts of fructus forsythiae, 15 to 20 parts of radix isatidis, 20 to 30 parts of radix astragali seu hedysari, 8 to 12 parts of radix platycodonis, 5 to 10 parts of Chinese gall, 10 to 15 parts of herba taraxaci and 8 to 12 parts of rhizoma polygoni cuspidati. Honeysuckle, gallnut and polygonum cuspidatum in the formula have the bacteriostatic effect, fructus forsythiae and isatis root can be used for resisting viruses, astragalus membranaceus can enhance the immunity of the organism, platycodon grandiflorum can promote intestinal development and improve digestion and absorption, dandelion has the effects of protecting liver, benefiting gallbladder and resisting inflammation, and after the Chinese herbal medicines are combined, the synergistic effects of resisting bacteria, resisting viruses and regulating immunity are achieved; the immunity of the shrimps and the digestion and absorption capability of the feed can be improved, and rapid and healthy growth of the shrimps is promoted.

The invention belongs to the field of veterinary biological products, and particularly relates to an O-type foot-and-mouth disease virus strain containing a VP1 T193A mutation site, a construction method of the O-type foot-and-mouth disease virus strain and application of the O-type foot-and-mouth disease virus strain in vaccine antigen escape research. According to the O-type foot-and-mouth disease virus mutant strain provided by the invention, threonine at the 193rd site of VP1 protein of a wild O-type foot-and-mouth disease virus strain is mutated into alanine. The amino acid sequence of the mutated VP1 protein is as shown in SEQ ID NO: 2. The lesion time, virus titer and growth curve of the mutant strain rVP1-T193A and rWT constructed by the invention are highly similar, but the neutralizing antibody titer of immune serum is reduced by 4.26 times, the corresponding r value is 0.23 and less than 0.3, and immune escape may be caused. Animal immune challenge protection experiments also prove that the VP1 T193A causes the FMDV to escape from vaccine immunity. The mutation significantly reduces the sensitivity of the virus to a neutralizing antibody, and can be used for researching a virus immune escape mechanism and optimizing vaccine design.

The present invention relates to a tumor therapy combining an oncolytic virus vaccine and immune cells in the field of biomedical technology. Specifically, it includes a step of treating a tumor by using immune cells and an oncolytic virus vaccine in combination, wherein the oncolytic virus vaccine contains recombinant oncolytic viruses that express tumor antigens and are intended to target tumor cells, and the immune cells are chimeric into antigen receptors that pair with the tumor antigens and are intended to kill or destroy the targeted tumor cells, and the recombinant oncolytic virus contains site-directed mutation M protein, G protein, N protein, P protein, and L protein. By using the oncolytic virus vaccine and immune cells that kill or destroy the tumor antigens, tumor cells are killed in a combined attack, the tumor antigens expressed by the oncolytic virus vaccine can not only guide immune cells to reach the center of the target tumor tissue, but the oncolytic virus, when used in combination with immune cells, kills tumor cells, achieving an effect greater than 1+1 = 2, and the tumor cell killing rate can reach up to 100%.

The invention provides akabane disease virus recombinant NSs protein, a preparation method and a kit, and relates to the technical field of biology. Recombinant expression of the akabane disease virus NSs protein is realized, and on the basis, a set of indirect ELISA detection method and kit for the akabane disease virus antibody are established, so that not only can the detection of the akabane disease virus antibody be realized, but also the distinguishing of akabane disease virus immune serum and infected serum can be realized.

The application obtains an anti-duck reovirus mu NS protein specific monoclonal antibody by immunizing mice with duck reovirus and a conventional monoclonal antibody preparation method, the hybridoma cell has a preservation number of CGMCC No.46129, the antibody secreted by the hybridoma cell is 3C3, a blocking ELISA detection method is constructed by using the antibody, and the method is compared with clinical serum detection, has the same result as a Western Blot method and an indirect immunofluorescence method, the method has high specificity, large throughput and low cost, and the result is intuitive, so that the demand of current primary duck reovirus monitoring can be met.

The application discloses a kit for efficiently knocking out a TRIM21 gene and application of the kit in reversing NDV oncolytic virus drug resistance. It is found through bioinformatics analysis and previous experimental verification that the expression level of the TRIM21 gene is related to the virus immunity of tumor cells, in order to improve the treatment effect of oncolytic virus anticancer treatment, several groups of shRNA are designed to specifically knock down TRIM21, and the knocking down effect is verified, and the experimental results show that after the TRIM21 is knocked down, the expression level of the NDV oncolytic virus in the glioma cells is significantly improved, and the highest reaches 3 times, which proves that the strategy has a significant effect on improving the treatment effect of oncolytic treatment, and has a wide application prospect.

The invention discloses a SOCS1 antagonistic peptide for preventing and treating avian infectious bronchitis and application of the SOCS1 antagonistic peptide, the amino acid sequence of the SOCS1 antagonistic peptide is LPQDKEYYKVKEP, and Y is phosphorylated tyrosine. Reasonable design is carried out on the basis of a molecular mechanism of interaction of a JAK2 activation ring and the SOCS1 protein, a molecular docking result shows that the SOCS1 antagonistic peptide can be precisely combined to KIR and SH2 functional domains of the chicken SOCS1 protein through a specific phosphorylated tyrosine residue of the SOCS1 antagonistic peptide, and the combination can competitively block combination of SOCS1 and endogenous JAK2 of cells, so that the chicken SOCS1 antagonistic peptide can be used for preparing the chicken SOCS1 antagonistic peptide. Therefore, the inhibition effect of SOCS1 on a JAK-STAT signal channel is relieved, the I-type interferon antiviral immune response of a host is recovered, and virus replication is inhibited fundamentally.

To provide an immune checkpoint-modulating VSV-NDV hybrid virus for oncolytic virus immunotherapy of cancer.SOLUTION: The invention relates to a recombinant oncolytic virus. The invention further relates to a nucleic acid encoding the recombinant oncolytic virus. The invention also relates to a nucleic acid vector comprising the nucleic acid encoding the recombinant oncolytic virus. Furthermore, the invention relates to a pharmaceutical composition comprising the recombinant oncolytic virus. Further, the invention relates to viruses, nucleic acids, vectors and pharmaceutical compositions for use in medicine, such as for use in the prevention and / or treatment of cancer. Moreover, the invention relates to the use of the virus, nucleic acid, vector and pharmaceutical composition as a gene delivery tool, (noninvasive) imaging of viral biodistribution and / or for tumor detection.SELECTED DRAWING: None